Introducing GPEx® Lightning: Next Gen Cell Line Engineering to Speed Your Path to Clinic
Summary: During this talk, we share the latest data leveraging GPEx Lightning to generate highly stable, highly productive cell pools and discuss how the GPEx suite of technologies can be tailored to the specific needs of each individual program on its path to clinical trials.
Manufacturing of New Modalities: New Opportunities Come With New Challenges
Summary: Dr. Mahdavi’s talk reviews key growth areas, innovative technologies and future strategies designed to increase the efficiency and scalability of advanced therapeutics.
The Post-COVID Pipeline Takes Shape: New Vaccines and Drugs During the mRNA Revolution
Summary: In this webinar, leaders in the field discuss new vaccines and drugs that have resulted from COVID and key learnings to prepare for the next pandemic.
ASCO Explained: Expert Predictions for the World’s Biggest Cancer Meeting
Summary: This roundtable discussion offers a closer look at oncology’s hottest fields, including CAR-T and precision medicine, 2021’s biggest research trends and the data they’re most looking forward to seeing.
Repurposing Drugs for New Indications: Benefits and Challenges
Summary: In this webinar executive summary, industry experts share diverse insights about challenges and opportunities with repurposing drugs for new disease treatments.
Then and Now – Delivering a Successful Therapeutic to Patients
Summary: Experts discuss the changing experience from the last quarter of a century in the pathway to patients, and how the latest advanced technologies translate into effective pre-clinical and clinical development and manufacturing.
Harnessing mRNA as a Readout to Develop Robust BioPotency Assays
Summary: Catalent has developed a relative potency bioassay using real-time quantitative reverse transcription (RT-qPCR) in a duplex format to assess relative transcription activity in cells treated with ligands or transgenic vectors.
Using GPEx® Technology for Development & Biomanufacturing of Difficult-to-express Proteins
Summary: The GPEx® suite of cell line development technologies has been utilized to develop hundreds of proteins, including difficult-to-express proteins, in a variety of mammalian cell lines.
A Collaborative Effort: How Parallel Approaches and Diverse Partnerships Could Help Combat COVID-19
Summary: In a panel discussion executives from Moderna, Sanofi Pasteur, Takeda and Catalent share behind-the-scenes updates on their respective efforts to develop a COVID-19 vaccine.
Innovations in ADC Technologies
Summary: There has been a lot of activity in the ADC market in the past 12-18 months in terms of licensing deals, acquisitions and investments. It’s likely no coincidence that this…
Pharma Predictions for 2021
Summary: Catalent CEO John Chiminski to talks about the year ahead, offering projections for what 2021 holds in store for the biopharma industry.
Women in Biopharma Awards 2020
Summary: Gwen Green, VP of Commercial Excellence at Catalent, and Endpoints News editors highlight the top 20 women in biopharma who have made it to the upper echelons of the drug development business in this on-demand webinar.
Supply Chain Contingencies to Avoid Upheaval
Summary: Karen Flynn, President of Biologics and Chief Commercial Officer, explains the challenges and opportunities changing how biomedical supply chains must plan and innovate to continue to serve patients and build resilient future options.
Catalent’s SMARTag® ADC Stands Out in the Crowd of HER2-targeted Conjugates
Summary: In a study published in Molecular Cancer Therapeutics, Catalent Biologics experts share the results of preclinical studies on their HER2-targeted ADC, CAT-01-106.
Advancements in ADCs Using SMARTag® Technology
Summary: Hear Penelope Drake, Director of R&D for Catalent Biologics, present on the demonstrated success of SMARTag® across several therapeutic modalities in this on-demand webinar.
BIO Europe: How COVID-19 is Bending the Curve on Vaccine Development and Manufacturing Norms
Summary: Hear from Mario Gargiulo, Catalent’s Region President, Biologics, Europe in this fireside chat interview with Dan Stanton, Editor and Founder, Bioprocess Insider.
Accelerating Manufacturing for Investigational COVID-19 Therapeutic Candidate Lenzilumab
Summary: Catalent Biologics presents a case study on the investigational COVID-19 therapeutic candidate, lenzilumab, and its development from gene to late stage clinical trials.
Disease Prevention & Control Summit 2020: Manufacturing Drugs & Vaccines Panel
Summary: This webinar discusses the challenges associated with pandemic drug manufacture and the extent to which vials that store vaccines could become a constraint, as well as the requirements that are needed in delivery systems and cold chain logistics.
Delivering Speed and Results through Advanced Technology and Collaboration
Summary: Enzymes can be challenging to express and scale up to become biologic therapies. In order to develop their optimized tissue plasmigen activator (tPA) to treat patients with hemorrhagic stroke…
The Future of Orphan Drugs: Insights on the Current Market, Trends & Strategic Partnerships Driving Innovation
Summary: In this report, we will highlight the trends shaping the orphan-drug market, with a particular focus on expedited drug development. Expert insights on navigating development and manufacturing challenges with…
How COVID-19 Is Bending the Curve on Vaccine Development and Manufacturing Norms
Summary: Hear Catalent Biologics Region President, address challenges in manufacturing scale-up and discuss how partnerships are enabling pharma companies of all sizes to meet unprecedented timelines as they race toward delivering vaccines to patients worldwide.
Cell Line Development Using the Beacon® Platform
Summary: Learn why speed and efficiency are top priorities for companies looking to develop a clonal cell line for drug substance manufacturing.
GPEx® Boost: A Novel Approach for High-Expressing CHO Cell Line Engineering
Summary: This webinar describes GPEx Boost technology in detail and discusses case study comparisons.
How COVID-19 Is Reshaping Vaccine Development: Innovations in Technology & Manufacturing Partnership
Summary: Experts provide an update on their partnership to enable and expedite scale-up to large-scale manufacturing and how it can be applied to future vaccine development.
Enabling Success in Biologic Drug Substance Development and Biomanufacturing
Summary: Biologic drug substance development and biomanufacturing is a critical step in the long, complex pathway to approval. There are many considerations to be made around…
TRPH-222 Interim Phase 1 Data: Enhancing Safety with SMARTag® Technology
Summary: Maximizing the therapeutic window and manufacturing well-defined ADCs are major challenges in the clinical development of ADCs. During this webinar, experts from Triphase Accelerator and…
Achieving Faster Timelines and Higher Titer in Antibody Expression When Combining GPEx® Cell Line Development Technology with the Beacon® Platform for Clonal Cell Line Selection
Summary: This case study explores Catalent’s unique GPEx® technology for stable gene product expression with Berkeley Lights, Inc.’s (BLI) Beacon® instrument for clonal selection.
Drug Manufacturing in a Time of Coronavirus
Summary: The COVID-19 pandemic has roiled R&D plans, created new priorities overnight and generally forced a major shift in many global manufacturing operations. This is an unprecedented…
How to Accelerate Early Drug Development in Oncology For Small Molecules and Biologics
Summary: Get an insight into what it takes to move a pre-clinical drug candidate to a Phase 1 clinical trial. The presentations will provide guidance on non-clinical and regulatory considerations…
Catalent Biologics | Cell Line Development
Summary: Your Strategic Partner for Biologics Development & Supply. As your trusted partner for tailored biologic solutions, we can help to bring your product…
Catalent Biologics | Downstream Processing
Summary: Your Strategic Partner for Biologics Development & Supply. As your trusted partner for tailored biologic solutions, we can help to bring your product…
Careers at Catalent Biologics
Summary: Catalent Biologics is a rapidly growing piece of our business. Learn what our employees are saying about what it’s like to work at Catalent Biologics.
Take Your Biologic to Clinic or Market, Faster
Summary: Biologic therapies are transforming the treatment of disease and improving the lives of millions. We have the passion to help you accelerate, simplify and de-risk…
GPEx® Boost: The Next Generation of Cell Line Development
Summary: GPEx® Boost is the next generation of cell line development, designed to improve productivity by leveraging proven GPEx® technology with multiple enhancements, including utilization of a glutamine synthetase…
OneBio Suite: Integrated Biologics Development, Manufacturing and Supply
Summary: OneBio™ Suite provides integrated biologics development, manufacturing and supply with a single solution from cell line development through clinical supply. OneBio Suite is designed…
GPEx® Boost – A Novel Approach for High-Expressing CHO Cell Line Development
Summary: Pharma companies are always examining ways to increase efficiencies and reduce cost of drug development. While cost of goods sold (COGS) can be…
GPEx® Boost Technology
Summary: Achieve higher titers by leveraging the power of proven GPEx® Technology with a glutamine synthetase knockout CHO cell line.
Rapid Global Characterization of Immunoglobulin G1 Following Oxidative Stress
Summary: While peroxide and leachable metal-induced chemical modifications are among the most important quality attributes in bioprocess development, there is no mainstream characterization method covering all common…
Analytical Quality by Design Using Design of Experiments
Summary: At the center of analytical Quality by Design (QbD) is Design of Experiment (DoE). Using DoE, assay development begins with the creation of an analytical target profile to define method objectives including critical method…
Embarking Upon the Commercial Manufacturing Journey For a Biologic: Strategies to Achieve Successful Approval & Launch
Summary: There are several key considerations to how sponsor companies should approach commercial-scale manufacturing that may aid the success of their product’s commercial launch. In some cases, there is a need to identify…
A Strategy to Standardize Process Characterization & Late Phase Development – Cell Culture Optimization
Summary: Process characterization is an important step in the overall journey of product development. For therapies that have had early success in the clinic and are progressing toward commercial
How to Choose the Best Partner for Biologics Development and Manufacturing
Summary: Biologic development is complex, requiring a significant amount of time and resources to ensure the best chance of success. Consequently, there are numerous aspects…
Biologics Brochure
Summary: Explore our suite of proprietary technology platforms and range of integrated development, manufacturing and clinical supply services. Catalent Biologics partners with leading biologic and…
Development Of An Intensified Fed-Batch Process Utilizing N-1 Perfusion And Ambr®15
Summary: While traditional fed-batch bioreactor process development has been well defined using methods such as shake flasks and bench-scale bioreactors, there is a desire to intensify…
Complex Protein Production
Summary: Download the eBook to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture medium and feed to maximize…
Evaluation of the 3M™ Emphaze™ AEX Hybrid Purifier
Summary: The 3M™ Emphaze™ AEX Hybrid Purifier is a novel purification tool that utilizes a Q-functional hydrogel and 0.2 μm membrane to reduce impurities…
A Strategy to Remove Formulation Development from the Critical Path
Summary: During this Q&A, Dr. Jun Lu, Director, Analytical Development at Catalent discusses how Catalent utilizes automation, specifically the UNcle® platform*, during formulation development…
Drug Substance Manufacturing Infocard
Summary: Catalent Biologics’ drug substance biomanufacturing services provide flexibility and scale to support your growth from clinical to commercial, with options to utilize single-use or stainless-steel bioreactors in a rigorous CGMP environment.
Trends in Biologics Manufacturing from Drug Substance to Fill/Finish
Summary: The biologics industry is growing rapidly with an estimated 40% of biopharmaceuticals in the industry pipeline. Consequently, pharmaceutical companies are strategically…
Systematic LC/MS/MS Investigations for the IND-Enabling Extended Characterization of Antibody–Drug Conjugate Modifications
Summary: ADCs are an important class of biologic drugs that are well-represented in clinical trials for oncology and other indications. These medicines harbor both…
Improving Efficiencies In Biomanufacturing With Formulation Development And Continuous Processing
Summary: Pharma companies are constantly looking for ways to save money within their operations. One way of doing this is to improve upon efficiencies within its manufacturing…
A Solution To Ensure Quantity & Quality Of The Excipient Polysorbate-80 In Drug Formulations
Summary: Polysorbate-80 (PS-80) is a surfactant commonly used as an excipient to improve API stability. However, degradation of PS-80 can lead to decreased drug potency or stability…
Comparing Continuous And Batch Processing In Downstream Purification
Summary: Current state-of-the-art continuous manufacturing technologies are being developed and implemented to manufacture a wide variety of products including monoclonal antibodies, recombinant proteins, and other biological modalities…
New Techniques for Analytical “Bioassay” Cell Banking
Summary: The creation of a reliable bioassay requires dependable master and working analytical cell banks. In this interview with Pharmaceutical Technology, Michael Sadick, Ph.D., principal scientist at Catalent Biologics, explains…
Continuous Processing In Biomanufacturing
Summary: As the biologics industry continues to grow, biopharmaceutical companies are evaluating continuous processing as a potential means to improve efficiencies. There are many factors to consider when determining whether continuous processing should be adopted, and if so, what adoption strategy should be used…
An Emerging Playbook For Antibody Drug Conjugates: Lessons From The Laboratory & Clinic Suggest A Strategy For Improving Efficacy And Safety
Summary: Antibody drug conjugates (ADCs) have become de rigueur for pharmaceutical oncology drug development pipelines. There are more than 40 ADCs undergoing clinical trials and many more in preclinical development…
The Next Step In Homogeneous Bioconjugate Development
Summary: Bringing a new biologic drug to the market is a long and expensive process with R&D cycles that can span more than 15 years and cost over a billion dollars. Nonetheless the pharma industry is increasingly shifting efforts to focus on these types of compounds…
ADC Development Using SMARTag™ Technology
Summary: Bioconjugates are an emerging class of biologics that combine the favorable properties of proteins, such as specificity and the ability to target distinct protein interfaces, with the advantages of synthetic small molecules, such as potency, bioavailability, and synthetic tractability. Early examples of bioconjugates include proteins linked to…
Reconstitution Of Formylglycine-generating Enzyme With Copper(II) For Aldehyde Tag Conversion
Summary: To further our aim of synthesizing aldehyde-tagged proteins for research and biotechnology applications, we developed methods for recombinant production of aerobic formylglycinegenerating enzyme (FGE) in good yield…
Designing Optimized, Site-Specific ADCs
Summary: Antibody-drug conjugates have provided a breakthrough in targeted medicines but ways of increasing their stability and efficacy are still required. Historically, the technologies used to build these two approved products result in a heterogeneous milieu of conjugates…
Viral Clearance For Biopharmaceutical Downstream Processes
Summary: Viral clearance studies are mandated prior to entering clinical trials and for commercial launch of biopharmaceuticals. These studies are a key component of risk mitigation to reduce the potential for iatrogenic transmission of pathogenic viruses. This paper reviews regulatory guidance and practical strategies for designing viral clearance studies…
Generating Aldehyde-Tagged Antibodies
Summary: This article is a selection of articles published in BioMed Central Ltd., giving overview on the ability to site-specifically conjugate a protein to a payload of interest has found widespread application in basic research and drug development…
New Ideas For Antibody-Drug Conjugate Design
Summary: This article is a selection of articles published in The Scientist, giving overviews on new ideas for antibody-drug conjugates designs so oncologists can aim a chemical payload at any cell for which they can identify a specific antigen, such as the HER2 receptor on breast cancer cells…
Enabling Higher Post Protein A Product Purity Using Novel Chromatographic Clarification
Summary: In the recent years, multiple optimizations and advances have been made to the classic antibody generation process to make it scalable, reproducible, and commercially viable. This article describes a strategy to get consistent highly pure products…
What Role Do Biologics Play In The Fight Against Disease?
Summary: Jennifer Mitcham, SMARTag™ business development, Catalent Biologics, offers insight into the new generation of antibody drug conjugates and the increasing importance biologics play in the fight against disease…
Optimizing Titer And Use Of A Specific Enzyme For Generating A Fully Processed Antibody
Summary: In Biologics, the market climate requires increasing speed to move the product to the next phase of development. Even before a product is proven effective in clinical trials, several decisions must be made…
Get To Clinic Faster: Navigating Complex Biologics Through Development And Manufacturing
Summary: In Biologics, the market climate requires increasing speed to move the product to the next phase of development. Even before a product is proven effective in clinical trials, several decisions must be made…
Novel Analytical Techniques For Monoclonal Antibodies
Summary: With the rising interest in biopharmaceuticals, drug developers need to quickly understand and evaluate the binding of therapeutic antibodies to Fc receptors. In this interview with Pharmaceutical Technology, Michael Sadick, Ph.D., and Dan Papa, Ph.D., of Catalent Biologics, talk about a new analytical testing panel…
The Ever-increasing Attraction of Biologics
Summary: The field of biologics promises targeted treatments for a range of conditions. For the promise of many of these therapies to become a reality, however, technological challenges must still be overcome, with many exciting novel treatments currently on, or making their way to, the market. This article published in Chemistry World discusses…
Moving A Complex Protein From Development To Large-Scale Clinical Production
Summary: The number of more complex biopharmaceuticals in development continues to increase. These include molecules like virus-like particle vaccines, proteins that require cleavage, or other additional post-translational modifications not typically performed by CHO cells, and more recently, numerous different multi-specific antibody platforms…
Single-Use Bioreactors Pose E&L Challenges
Summary: Read the recent roundtable Q&A published in BioPharm International featuring biopharma executives discussing the challenges posed by single-use bioreactor bags in contributing to extractables and leachables in the biomanufacturing process…
Accelerating Biologics And Biosimilar Development
Summary: Get to know how Catalent’s scientists have utilized ambr 15® as a micro-scale model for a synergistic clonal and process screen to identify the master cell bank candidates. Using this multi-layered approach, early in the development process significantly improves selection of top clones while shortening the overall timeline…
Biosimilars: Getting Cheaper Biologics To The Market
Summary: The opportunity for new antibody biosmilar products is clear. By the end of this decade key patents currently protecting five monoclonal antibodies, each with sales in the neighborhood of a billion dollars a year will have expired, and companies are queuing up for a piece of the market…
Get To Clinic Faster: Navigating Complex Biologics Through Development And Manufacturing
Summary: With the increasing complexity of biologics and growing competition with players ranging from small start-ups to large pharma, an aggressive development timeline is required to bring your biologic drug to clinic faster…
Biopharmaceuticals/ Biosimilars Roundtable, APR 2017
Summary: The biopharmaceutical market has seen incredible growth. American Pharmaceutical Review conducted industry round table with experts to share their opinion on the market drivers for growth, limiting factors and critical issues. Read the article to get insights on developing and marketing biopharmaceutical…
Developing Site-Specifically Modified ADCs Using A Chemoenzymatic Approach
Summary: Antibody-drug conjugates (ADCs) have become de rigueur for pharmaceutical oncology drug development pipelines. There are more than 40 ADCs undergoing clinical trials and many more in preclinical development. This webinar hosted by Elsevier’s Drug Discovery Today presented novel protein modification platform and its application…
Evolution Of Biomanufacturing Facilities
Summary: Advances in single-use bioreactor technologies offer rapid development pathways when combined with creative upstream process development strategies. When aggressive program timelines are required, the application of multiplexed conditions coupled with smart CMC decisions that maximize yields…
Virus Safety Of Biopharmaceuticals: Risk Mitigation During Upstream And Downstream Operations
Summary: From a virological safety standpoint, biopharmaceuticals have had an excellent safety record. This can be attributed to regulatory and industry initiatives that have worked synergistically…
Recent Developments In ADC Technology: Preclinical Studies Signal Future Clinical Trends
Summary: The antibody-drug conjugate (ADC) field is in a transitional period. Here, experts from Catalent discuss how pre-clinical work is driving rapid evaluation of how we strategize to improve efficacy and reduce toxicity towards better therapeutic outcomes…
Optimized Antibody Drug Conjugate Development
Summary: One of the current challenges with existing ADCs is the difficulty in creating conjugates with a uniform drug to antibody ratio and consistent payload placement on the antibody, both aspects which are paramount in creating consistent and predictable therapies…